Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.

Kielgast U, Krarup T, Holst JJ, Madsbad S

Diabetes care18 May 2011Cited by 130 (Europe PMC)

PMID21593296PMCIDPMC3120168DOI10.2337/dc11-0096PepBankPUB-21593296

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In type 1 diabetic patients without residual beta-cell function, liraglutide with background insulin lowered the daily insulin dose, whereas the dose did not change with insulin monotherapy.
In plain wordsIn people with type 1 diabetes who make no insulin, liraglutide lowered the insulin dose needed, but insulin alone did not.
Peptide
Liraglutide
Outcome
DecreaseInsulin dose change in C-peptide-negative patients
Study
n = 19
Comparator
Insulin monotherapy
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
Insulin dose before
0.72 units/kg per day
C-peptide negative, liraglutide
Insulin dose after
0.59 units/kg per day
C-peptide negative, liraglutide
Source sentences
Summary
Insulin dose decreased from 0.50±0.06 to 0.31±0.08 units/kg per day (P<0.001) in C-peptide-positive patients and from 0.72±0.08 to 0.59±0.06 units/kg per day (P<0.01) in C-peptide-negative patients treated with liraglutide but did not change with insulin monotherapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten type 1 diabetic patients with residual β-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied.
Summary · context
All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy.
Report a problemFND-2159329602
02HumanNon-randomized trialEfficacy outcome
In type 1 diabetic patients treated with liraglutide, 18 of 19 patients lost weight during treatment.
In plain wordsIn people with type 1 diabetes, 18 of 19 patients given liraglutide lost weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 19
Comparator
Baseline (week 0)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
Mean weight change
−2.3 kg
liraglutide-treated patients
Source sentences
Summary
A total of 18 of 19 patients treated with liraglutide lost weight during treatment (mean [range] -2.3±0.3 kg [-0.5 to -5.1]; P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Ten type 1 diabetic patients with residual β-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied.
Summary · context
All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy.
Report a problemFND-2159329607
03HumanNon-randomized trialEfficacy outcome
In type 1 diabetic patients with residual beta-cell function, 4 weeks of liraglutide with background insulin lowered the daily insulin dose.
In plain wordsIn people with type 1 diabetes who still make some insulin, liraglutide lowered the insulin dose needed.
Peptide
Liraglutide
Outcome
DecreaseInsulin dose change in C-peptide-positive patients
Study
n = 10
Comparator
Baseline (week 0)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
Insulin dose before
0.5 units/kg per day
C-peptide positive
Insulin dose after
0.31 units/kg per day
C-peptide positive
Source sentences
Summary
Insulin dose decreased from 0.50±0.06 to 0.31±0.08 units/kg per day (P<0.001) in C-peptide-positive patients and from 0.72±0.08 to 0.59±0.06 units/kg per day (P<0.01) in C-peptide-negative patients treated with liraglutide but did not change with insulin monotherapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten type 1 diabetic patients with residual β-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied.
Summary · context
All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy.
Report a problemFND-2159329601
04HumanNon-randomized trialEfficacy outcome
In C-peptide-positive type 1 diabetic patients, liraglutide treatment reduced the time spent with blood glucose below 3.9 mmol/L.
In plain wordsIn people with type 1 diabetes who still make some insulin, liraglutide shortened the time with low blood sugar.
Peptide
Liraglutide
Outcome
DecreaseTime with blood glucose below 3.9 mmol/L
Study
n = 10
Comparator
Baseline (week 0)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Measurements
Time with glucose <3.9 mmol/L, before
3 h
C-peptide positive
Time with glucose <3.9 mmol/L, after
1 h
C-peptide positive
Source sentences
Summary
In C-peptide-positive patients, time spent with blood glucose<3.9 mmol/L decreased from 3.0 to 1.0 h (P=0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
Ten type 1 diabetic patients with residual β-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied.
Summary · context
All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy.
Report a problemFND-2159329606
05HumanNon-randomized trialEfficacy outcome
In type 1 diabetic patients treated with liraglutide on background insulin, HbA1c decreased in both the C-peptide-positive and C-peptide-negative groups.
In plain wordsIn people with type 1 diabetes, HbA1c fell in both groups that received liraglutide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Comparator
Baseline (week 0)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Source sentences
Summary
HbA1c decreased in both liraglutide-treated groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten type 1 diabetic patients with residual β-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied.
Summary · context
All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy.
Report a problemFND-2159329603
06HumanNon-randomized trialMechanism
In type 1 diabetic patients treated with liraglutide, the percent reduction in daily insulin dose correlated positively with baseline beta-cell function.
In plain wordsIn people with type 1 diabetes, a bigger drop in insulin dose was linked to better beta-cell function at the start.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of insulin dose reduction with baseline beta-cell function
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Source sentences
Summary
The percent reduction in daily insulin dose was positively correlated with β-cell function at baseline
2 context sentences(design, population, supporting numbers)
Summary · context
Ten type 1 diabetic patients with residual β-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied.
Summary · context
All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy.
Report a problemFND-2159329604
07HumanNon-randomized trialEfficacy outcome
In type 1 diabetic patients treated with liraglutide, two patients discontinued insulin treatment.
In plain wordsIn people with type 1 diabetes given liraglutide, two patients stopped insulin treatment.
Peptide
Liraglutide
Outcome
Not applicableDiscontinuation of insulin treatment
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Source sentences
Summary
two patients discontinued insulin treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten type 1 diabetic patients with residual β-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied.
Summary · context
All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy.
Report a problemFND-2159329605
08HumanNon-randomized trialSafety outcome
In type 1 diabetic patients, transient gastrointestinal adverse effects occurred in almost all patients treated with liraglutide.
In plain wordsIn people with type 1 diabetes, almost everyone given liraglutide had short-lived stomach and gut side effects.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal adverse effects
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 4 weeksAs given in this study (human).
Source sentences
Summary
Transient gastrointestinal adverse effects occurred in almost all patients treated with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten type 1 diabetic patients with residual β-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied.
Summary · context
All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy.
Report a problemFND-2159329608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2/3NCT00993720

Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes

Hvidovre University Hospitaln = 30Oct 2009 to Oct 2010

Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 21 Jan 2011

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.